Statement: the ability to orally ingest medication is a requisite for patients participating in the primary clinical trial
Primary_evidence: Inclusion criteria:   Signed Informed Consent   ErbB2(HER2)overexpressing breast cancer.   Brain lesion(s) which are progressing.   Prior treatment of brain metastases with Whole Brain Radiotherapy (WBR)and/or Stereotactic Radiosurgery (SRS).   Prior treatment with trastuzumab (Herceptin), either alone or in combination with chemotherapy.   Cardiac ejection fraction(LVEF)within the institutional range of normal as measured by Echocardiogram.   Able to swallow an oral medication.   Adequate kidney and liver function.   Adequate bone marrow function. Exclusion criteria:   Pregnant or lactating females.   Conditions that would effect the absorption of an oral drug.   History of immediate or delayed hypersensitivity reaction to gadolinium contrast agents.   Pre-existing severe cerebral vascular disease, such as stroke involving a major vessel.   Serious medical or psychiatric disorder that would interfere with the patient's safety or informed consent.